Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03899805
Recruitment Status : Recruiting
First Posted : April 2, 2019
Last Update Posted : June 7, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Michael J. Nathenson, Dana-Farber Cancer Institute

Brief Summary:
This research study is studying a combination of drugs (chemotherapy + Immunotherapy) as a possible treatment for liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma that has spread and has not responded to standard treatment.

Condition or disease Intervention/treatment Phase
Sarcoma Liposarcoma Leiomyosarcoma Undifferentiated Pleomorphic Sarcoma Drug: Eribulin Drug: Pembrolizumab Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug, or in the case of this study, combination of drugs, to learn whether the combination of drugs works in treating a specific disease. "Investigational" means that the combination of drugs is being studied.

The primary purpose of this research study is to test the safety and effectiveness of eribulin and pembrolizumab in combination for controlling this cancer

The FDA (the U.S. Food and Drug Administration) has approved eribulin for the treatment of liposarcoma, based on a phase III study that compared eribulin and dacarbazine in the treatment of liposarcoma and leiomyosarcoma. The FDA has not approved pembrolizumab for this specific disease but it has been approved for other uses. A phase II study showed rare responses of liposarcoma and undifferentiated pleomorphic sarcoma to treatment with pembrolizumab. While eribulin in combination with pembrolizumab has not previously been tested in the treatment of liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma, other research studies and laboratory experiments and information from those studies suggest that the combination of these drugs may help to stop cancer cells from growing. Chemotherapy treatment with eribulin may increase the response to immunotherapy with pembrolizumab


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Actual Study Start Date : May 13, 2019
Estimated Primary Completion Date : August 1, 2022
Estimated Study Completion Date : August 1, 2024


Arm Intervention/treatment
Experimental: Liposarcomas
  • Participants will receive eribulin intravenously on Day 1 and Day 8
  • Pembrolizumab is administered intravenously Day 1, on a 21-day cycle
Drug: Eribulin
The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
Other Name: Halaven

Drug: Pembrolizumab
The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
Other Name: Keytruda

Experimental: Leiomyosarcomas
  • Participants will receive eribulin intravenously on Day 1 and Day 8
  • Pembrolizumab is administered intravenously Day 1, on a 21-day cycle
Drug: Eribulin
The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
Other Name: Halaven

Drug: Pembrolizumab
The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
Other Name: Keytruda

Experimental: Undifferentiated Pleomorphic sarcomas
  • Participants will receive eribulin intravenously on Day 1 and Day 8
  • Pembrolizumab is administered intravenously Day 1, on a 21-day cycle
Drug: Eribulin
The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
Other Name: Halaven

Drug: Pembrolizumab
The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
Other Name: Keytruda




Primary Outcome Measures :
  1. Rate of Progression Free Survival [ Time Frame: Time from start of treatment to time of progression or death, whichever occurs first, assessed at 12 weeks ]
    For the primary endpoint of progression-free survival at 12 weeks with a null hypothesis of 30% and an alternative hypothesis of 60%, at least 9 patients absent of disease progression out of 19 patients will need to be observed to accept the treatment. The overall power for progression-free survival rare at 12 weeks is 91%. The overall type I error, the chance of incorrectly rejecting the null hypothesis is 10%.


Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: Up to 2 years ]
    Time from start of treatment to time of death.

  2. Objective Response Rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [ Time Frame: Assessed at 12 weeks ]
    Objection response rate is the rate of complete response and partial response per RECIST 1.1.

  3. Clinical Benefit Response Rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [ Time Frame: Assessed at 12 weeks ]
    Clinical benefit rare is the rate of complete response and partial response and stable disease per RECIST 1.1.

  4. Incidence of toxicity, grade using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. [ Time Frame: Up to 2 Years ]
    Among the 19 patients in each arm, there is a least a 86% probability of observing one or more toxicities with a true rate as low as 10%. With 19 treated patients in each arm, the maximum width of a 90% two-sided confidence interval for any estimated adverse event proportion is +/- 20%.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed liposarcoma, leiomyosarcoma, or undifferentiated/unclassified pleomorphic sarcoma by a Dana-Farber Cancer Institute or Massachusetts General Hospital pathologist
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. See Section 11 for the evaluation of measurable disease.
  • Participants must have received at least one prior line of chemotherapy. No limit on prior lines of therapy.
  • Age ≥ 18 years.
  • ECOG performance status of 0 or 1 (see Appendix A).
  • Participants must have normal organ and marrow function as defined below:

    • leukocytes ≥3,000/mcL
    • absolute neutrophil count ≥1,500/mcL
    • platelets ≥100,000/mcL
    • Hemoglobin ≥ 8 g/dL within the first 2 weeks prior to the first dose of study drugs, transfusion is allowed.
    • total bilirubin ≤1.5× institutional upper limit of normal (ULN) (except participants with Gilbert Syndrome, who can have total bilirubin <3.0 mg/dL)
    • AST(SGOT)/ALT(SGPT)<2.5 x ULN in a participant with no documented liver metastases; ALT and AST <5.0 x ULN in a participant with documented liver metastases
    • creatinine ≤1.5× ULN OR
    • creatinine clearance ≥50 mL/min/1.73 m2 for participants with creatinine levels above institutional normal (using the Cockcroft-Gault Formula below):
    • Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL
    • Male CrCl = (140 - age in years) x weight in kg 72 x serum creatinine in mg/dL
  • Available archival tumor tissue including Formalin-fixed, paraffin embedded (FFPE) or fresh frozen, or be willing to undergo baseline biopsy for tumor tissue correlative biomarker studies.
  • The effects of eribulin and pembrolizumab on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. A male participant must agree to use a contraception as detailed in Appendix G of this protocol during the treatment period and for at least 20 weeks, corresponding to the time needed to eliminate any study treatments, plus an additional 120 days (a spermatogenesis cycle) after the last dose of study treatment. A female participant is eligible to participate if she is not pregnant (see Appendix G), not breastfeeding, and at least one of the following conditions applies:

    • Not a woman of childbearing potential (WOCBP) as defined in Appendix G OR
    • A WOCBP who agrees to follow the contraceptive guidance in Appendix G during the treatment period and for at least 20 weeks plus an additional 30 days (a menstruation cycle) after the last dose of study treatment.
    • WOCBP should use an adequate method to avoid pregnancy for at least 20 weeks plus an additional 30 days after the last dose of investigational drug. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the start of Eribulin and Pembrolizumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception. Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.
    • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Participants who have had standard chemotherapy or radiotherapy within 3 weeks prior to entering the study.
  • Participants who have not recovered from adverse events (grade 2 or higher toxicities) due to agents administered, radiotherapy, or surgery more than 3 weeks earlier, with the exception of alopecia.
  • Previous treatment with eribulin or any anti-PD-1, PD-L1, or PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
  • Participants who are currently participating in or have participated in a study of an investigational agent or have used an investigational device within 3 weeks prior to the first dose of study treatment.
  • Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 3 weeks after the last dose of the previous investigational agent.
  • Known brain metastases that are untreated, symptomatic or require therapy to control symptoms. Participants with previously diagnosed brain metastases are eligible if they have completed treatment at least 4 weeks prior to registration, are neurologically stable and have not experienced any new neurologic symptoms for the last 4 weeks prior to study entry, and have recovered from the effects of radiotherapy or surgery. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. Treatment for brain metastases may have included whole brain radiotherapy, radiosurgery, surgery, or a combination as deemed appropriate by the treating physician.
  • Have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
  • Inability to comply with study and/or follow-up procedures.
  • History of severe hypersensitivity reaction (≥Grade 3) to any monoclonal antibody.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Eribulin or Pembrolizumab.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations which in the PI's opinion makes it undesirable for the participant to participate in the trial or which would jeopardize compliance with the trial and study requirements.
  • Pregnant women (WOCBP who had a positive serum pregnancy test on screening or 72 hours prior to initiation of study protocol) are excluded from this study because the effects of Eribulin and Pembrolizumab on the developing fetus are unknown. There is the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Eribulin and Pembrolizumab, breastfeeding should be discontinued if the mother is treated with Eribulin and Pembrolizumab.
  • Because the effects of pembrolizumab on chronic viral infection are not well known, participants should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) (true positive) or known acquired immunodeficiency syndrome (AIDS) or if they have a positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
  • Participants with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded. These include but are not limited to participants with a history of immune related neurologic disease such as multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, or myasthenia gravis; participants with a history of systemic autoimmune disease such as SLE, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, or hepatitis; and participants with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome. These participants should be excluded because of the risk of recurrence or exacerbation of disease. Participants with vitiligo or endocrine deficiencies, including thyroiditis managed with replacement hormones such as physiologic corticosteroids, are eligible. Participants with rheumatoid arthritis or other arthropathies; Sjögren's syndrome; psoriasis controlled with topical medication; or participants with positive serology, such as antinuclear antibodies (ANA) or anti-thyroid antibodies, should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.
  • Participants are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event).
  • Participants should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses <10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Participants are permitted to use topical, ocular, intraarticular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if <10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
  • Participants with a history of pneumonitis or interstitial lung disease.
  • History of primary immunodeficiency or solid organ transplantation.
  • Participants who have had evidence of active or acute diverticulitis, intra-abdominal abscess, GI obstruction, or fistula or abdominal carcinomatosis (which are known risk factors for bowel perforation) should be evaluated for the potential need for additional treatment before coming on study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03899805


Contacts
Layout table for location contacts
Contact: Michael Nathenson, MD 617-632-5204 Michaelj_nathenson@dfci.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Cancer Center Recruiting
Boston, Massachusetts, United States, 02114
Contact: Edwin Choy, MD       echoy@partners.org   
Principal Investigator: Edwin Choy, MD         
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Michael Nathenson, MD    617-632-5204    Michaelj_nathenson@dfci.harvard.edu   
Principal Investigator: Michael Nathenson, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Michael Nathenson, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Michael J. Nathenson, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03899805     History of Changes
Other Study ID Numbers: 19-082
First Posted: April 2, 2019    Key Record Dates
Last Update Posted: June 7, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: BCH - Contact the Technology & Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu BIDMC - Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu BWH - Contact the Partners Innovations team at http://www.partners.org/innovation DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu MGH - Contact the Partners Innovations team at http://www.partners.org/innovation

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Michael J. Nathenson, Dana-Farber Cancer Institute:
Sarcoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Leiomyosarcoma
Liposarcoma
Histiocytoma, Malignant Fibrous
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Muscle Tissue
Neoplasms, Adipose Tissue
Histiocytoma
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents